Pharmacotherapy of schizophrenia patients with comorbid substance abuse

Schizophrenia Bulletin

Volumn 23, Issue 2, 1997, Pages 215-228

  Wilkins, Jeffery N ^a,b  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACAMPROSATE; ALCOHOL; AMANTADINE; AMOXAPINE; BACLOFEN; CAFFEINE; CANNABINOID; CHOLINERGIC RECEPTOR BLOCKING AGENT; CITALOPRAM; COCAINE; DESIPRAMINE; DEXAMPHETAMINE; DISULFIRAM; DOPAMINE 1 RECEPTOR STIMULATING AGENT; DOPAMINE 2 RECEPTOR BLOCKING AGENT; FLUOXETINE; FLUPENTIXOL; IMIPRAMINE; NALTREXONE; NEUROLEPTIC AGENT; NICOTINE; OPIATE AGONIST; OPIATE ANTAGONIST; PEMOLINE; SELEGILINE; SEROTONIN 1A AGONIST; SEROTONIN 2 ANTAGONIST; TIAPRIDE; TRYPTOPHAN; UNINDEXED DRUG;

ARTICLE; CLINICAL TRIAL; COMORBIDITY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEPRESSION; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG DEPENDENCE; DRUG MECHANISM; EXTRAPYRAMIDAL SYMPTOM; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MAJOR CLINICAL STUDY; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; PROGNOSIS; RANDOMIZED CONTROLLED TRIAL; SCHIZOPHRENIA; SUBSTANCE ABUSE;

EID: 0030925440     PISSN: 05867614     EISSN: None     Source Type: Journal    
DOI: 10.1093/schbul/23.2.215     Document Type: Article

References (98)

1. Adler, L.E.; Hoffer, L.D.; Wiser, A.; and Freedman, R. Normalization of auditory physiology by cigarette smoking in schizophrenic patients. American Journal of Psychiatry, 150:1856-1861, 1993.
2. Alterman, A.I., and Erdlen, D.L. Illicit substance use in hospitalized psychiatric patients: Clinical observations. Journal of Psychiatric Treatment and Evaluation, 5:377-380, 1983.
3. American Psychiatric Association. "Practice Guidelines for the Treatment of Patients With Substance Use Disorders: Alcohol, Cocaine, Opioids." American Journal of Psychiatry, 152(Suppl. 11):4-59, 1995.
4. American Psychiatric Association. "Practice Guidelines for the Treatment of Patients With Nicotine Dependence." American Journal of Psychiatry, 153(Suppl 10):1-31, 1996.
5. Andreasen, N.C. The Scale for the Assessment of Negative Symptoms (SANS). Iowa City, IA: The University of Iowa, 1984a.
6. Andreasen, N.C. The Scale for the Assessment of Positive Symptoms (SAPS). Iowa City, IA: The University of Iowa, 1984b.
7. Andreasson, S.; Allebeck, P.; Engstrom, A.; and Rydberg, U. Cannabis and schizophrenia: A longitudinal study of Swedish conscripts. Lancet, II:1483-1486, 1987.
8. Arndt, I.O.; Dorozynsky, L.; Woody, G.E.; McLellan, A.T.; and O'Brien, C.P. Desipramine treatment of cocaine dependence in methadone-maintained patients. Archives of General Psychiatry, 49:893-898, 1992.
9. Baberg, H.T.; Nelesen, R.A.; and Dimsdale, J.E. Amphetamine use: Return of an old scourge in a consultation psychiatry setting. American Journal of Psychiatry, 153(6):789-793, 1996.
10. Beck, A.T.; Ward, C.H.; Mendelson, M.; Mock, J.; and Erbaugh, J.K. An inventory for measuring depression. Archives of General Psychiatry, 4:561-571, 1961.
11. Berger, S.P.; Gawin, F.; and Kosten, T.R. Treatment of cocaine abuse with mazindol. Lancet, I:283, 1989.
12. Berger, S.P.; Hall, S.; Mickalian, J.D.; Reid, M.S.; Crawford, C.A.; Delucchi, K.; Carr, K.; and Hall, S. Haloperidol antagonism of cue-elicited cocaine craving. Lancet, 347:504-508, 1996.
13. Bowers, M.B.; Mazure, C.M.; Nelson, J.C.; and Jatlow, P.I. Psychotogenic drug use and neuroleptic response. Schizophrenia Bulletin, 16(1):81-85, 1990.
14. Brady, K.; Anton, R.A.; Ballenger, J.C.; Lydiard, R.B.; Adinoff, B.; and Selander, J. Cocaine abuse among schizophrenic patients. American Journal of Psychiatry, 147(9):1164-1167, 1990.
15. Brady, K.; Casto, S.; and Lydiard, R.B. Substance abuse in an inpatient psychiatric sample. American Journal of Drug and Alcohol Abuse, 17:389-397, 1991.
16. Breakey, W.R.; Goodell, H.; Lorenz, P.C.; and McHugh, P.R. Hallucinogenic drugs as precipitants of schizophrenia. Psychological Medicine, 4:255-261, 1974.
17. Buckley, P.; Thompson, P.A.; Way, L.; and Meltzer, H.Y. Substance abuse among patients with treatment-resistant schizophrenia: Characteristics and implications for clozapine therapy. American Journal of Psychiatry, 151(3):385-389, 1994a.
18. Buckley, P.; Thompson, P.A.; Way, L.; and Meltzer, H.Y. Substance abuse and clozapine treatment. Journal of Clinical Psychiatry, 55:114-116, 1994b.
19. 2 stimulation and blockade on smoking behavior. Experimental and Clinical Psychopharmacology, in press.
20. Childress, A.R.; Ehrman, R.; Rohsenow, D.J.; Robbins, S.J.; and O'Brien, C.P. Classically conditioned factors in drug dependence. In: Lowinson, J.H.; Ruiz, P.; and Millman, R.B., eds. Substance Abuse: A Comprehensive Textbook. Baltimore, MD: Williams and Wilkins Company, 1992. pp. 56-69.
21. Derogatis, L.; Lipman, R.; and Covi, L. SCL-90: An outpatient psychiatric rating scale - Preliminary report. Psychopharmacology Bulletin, 9(1):13-17, 1973.
22. Dixon, L.; Haas, G.; Weiden, P.J.; Sweeney, J.; and Frances, A.J. Drug abuse in schizophrenic patients: Clinical correlates and reasons for use. American Journal of Psychiatry, 148(2):224-230, 1991.
23. Dixon, L.; Weiden, P.J.; Haas, G.; Sweeney, J.; and Frances, A.J. Increased tardive dyskinesia in alcohol-abusing schizophrenic patients. Comprehensive Psychiatry, 33(2):121-122, 1992.
24. Endicott, J.; Spitzer, R.L.; Fleiss, J.L.; and Cohen, J. The Global Assessment Scale - A procedure for measuring overall severity of psychiatric disturbance. Archives of General Psychiatry, 33:766-771, 1976.
25. Flaum, M., and Schultz, S. When does amphetamine-induced psychosis become schizophrenia? American Journal of Psychiatry, 153(6):812-815, 1996.
26. Freed, E.X. Alcoholism and schizophrenia: The search for perspectives: A review. Journal of Studies on Alcohol, 36(7):853-881, 1975.
27. Fulton, M.K.; Kramer, G.; Moeller, F.G.; Chae, Y.; Isbell, P.G.; and Petty, F. Low plasma homovanillic acid levels in recently abstinent alcoholic men. American Journal of Psychiatry, 152(12):1819-1820, 1995.
28. Galanter, M.; Castaneda, R.; and Ferman, J. Substance abuse among general psychiatric patients: Place of presentation, diagnosis, and treatment. American Journal of Drug and Alcohol Abuse, 14(2):211-235, 1988.
29. Garcia, L.C. Dependencia a anticolinergicos en esquizofrenicos: Iatrogenia o automedication? (Anticholinergic dependence in schizophrenics: Iatrogenic or automedication?). Actas Luso-Espanolas de Neurologia, Psiquiatria y Ciencias Afines, 19(6):298-303, 1991.
30. Gawin, F.H. Neuroleptic reduction of cocaine-induced paranoia but not euphoria? Psychopharmacology, 90:142-143, 1986.
31. Gawin, F.H.; Allen, D.; and Humblestone, B. Outpatient treatment of "crack" cocaine smoking with flupenthixol decanoate. Archives of General Psychiatry, 46:322-325, 1989.
32. Gawin, F.H., and Ellinwood, E.H. Cocaine and other stimulants: Actions, abuse, and treatment. New England Journal of Medicine, 318:1173-1182, 1988.
33. Gawin, F.H., and Kleber, H.D. Abstinence symptomatology and psychiatric diagnosis in chronic cocaine abusers. Archives of General Psychiatry, 43:107-113, 1986.
34. Goff, D.C.; Guochuan, T.; Manoach, D.S.; and Coyle, J.T. Dose-finding trial of D-cycloserine added to neuroleptics for negative symptoms in schizophrenia. American Journal of Psychiatry, 152(8):1213-1215, 1995.
35. Goff, D.C.; Henderson, D.C.; and Amico, E. Cigarette smoking in schizophrenia: Relationship to psychopathology and medication side effects. American Journal of Psychiatry, 149(9):1189-1194, 1992.
36. Greden, J.F., and Walters, A. Caffeine. In: Lowinson, J.H.; Ruiz, P.; Millman, R.B.; and Langrod, J.G., eds. Substance Abuse: A Comprehensive Textbook. 2nd ed. Baltimore, MD: Williams and Wilkins Company, 1992. pp. 357-370.
37. Griffiths, R.R.; Bigelow, G.E.; and Liebson, I.A. Human coffee drinking: Reinforcing and physical dependence producing effects of caffeine. Journal of Pharmacology and Experimental Therapeutics, 239(2):416-425, 1986.
38. Gritz, E.R.; Stapleton, J.M.; Hill, M.A.; and Jarvik, M.E. Prevalence of cigarette smoking in medical and psychiatric hospitals. Bulletin of the Society of Psychologists in Addictive Behaviors, 4(3):151-165, 1985.
39. Guy, W., ed. ECDEU Assessment Manual for Psychopharmacology, revised. Rockville, MD: National Institute of Mental Health, DHEW Publication No. (ADM)76-338, 1976.
40. 3 receptors and cerebral dopamine function: Implications for the treatment of schizophrenia and psychoactive substance abuse. Psychopharmacology, 112(Suppl.):68-75, 1993.
41. Hamilton, M. The assessment of anxiety states by rating. British Journal of Medical Psychology, 32:50-55, 1959.
42. Hartman, N.; Leong, G.B.; Glynn, S.M.; Wilkins, J.N.; and Jarvik, M.E. Transdermal nicotine and smoking behavior in psychiatric patients. American Journal of Psychiatry, 148:374-375, 1991.
43. Haywood, T.A.; Kravitz, H.M.; Grossman, L.S.; Cavanaugh, J.L.; Davis, J.M.; and Lewis, D.A. Predicting the "revolving door" phenomenon among patients with schizophrenic, schizoaffective, and affective disorders. American Journal of Psychiatry, 152(6):856-861, 1995.
44. Higgins, S.T.; Budney, A.J.; Bickel, W.K.; Foerg, F.E.; Donham, R.; and Badger, G.J. Incentives improve outcome in outpatient behavioral treatment of cocaine dependence. Archives of General Psychiatry, 51:568-576, 1994.
45. Hogarty, G.E.; McEvoy, J.P.; Ulrich, R.F.; DiBarry, A.L.; Bartone, P.; Cooley, S.; Hammill, K.; Carter, M.; Munetz, M.R.; and Perel, J. Pharmacotherapy of impaired affect in recovering schizophrenic patients. Archives of General Psychiatry, 52:29-41, 1995.
46. Hyde, A.P. Response to "Effects of caffeine on behavior of schizophrenic inpatients." Schizophrenia Bulletin, 16(3):371-372, 1990.
47. Kapur, S., and Remington, G. Serotonin-dopamine interaction and its relevance to schizophrenia. American Journal of Psychiatry, 153(4):466-476, 1996.
48. Kingsbury, S.J., and Salzman, C. Disulfiram in the treatment of alcoholic patients with schizophrenia. Hospital and Community Psychiatry, 41(2):133-134, 1990.
49. Knudsen, P., and Vilmar, T. Cannabis and neuroleptic agents in schizophrenia. Acta Psychiatrica Scandinavica, 69:162-170, 1984.
50. Kofoed, L.; Kania, J.; Walsh, T.; and Atkinson, R. Outpatient treatment of patients with substance abuse and coexisting psychiatric disorders. American Journal of Psychiatry, 143(7):867-872, 1986.
51. Kosten, T.R. Pharmacotherapies. In: Kosten, T.R., and Kleber, H.D., eds. Clinician's Guide to Cocaine Addiction. New York, NY: Guilford Press, 1992. pp. 273-289.
52. Kosten, T.R.; Morgan, C.M.; Falcione, M.A.; and Schottenfeld, R.S. Pharmacotherapy for cocaine-abusing methadone-maintained patients using amantadine or desipramine. Archives of General Psychiatry, 49:894-898, 1992.
53. LeDuc, P.A., and Mittleman, G. Schizophrenia and psychostimulant abuse: A review and re-analysis of clinical evidence. Psychopharmacology, 121(4):407-427, 1995.
54. Leon, J.D.; Dadvand, M.; Canuso, C.; White, A.O.; Stanilla, J.K.; and Simpson, G.M. Schizophrenia and smoking: An epidemiological survey in a State hospital. American Journal of Psychiatry, 152(3):453-455, 1995.
55. Levin, F.R.; Evans, S.M.; Coomaraswammy, S.; Collins, E.D.; Regent, N.; and Kleber, H.D. "Flupenthixol Treatment for Cocaine Abusers With Schizophrenia: A Pilot Study." Submitted for publication.
56. Liberman, R.P., and Corrigan, P.W. Designing new psychosocial treatments for schizophrenia. Psychiatry, 56:236-249, 1993.
57. Liberman, R.P.; DeRisi, W.J.; and Mueser, R. Social Skills Training for Psychiatric Patients. New York, NY: Pergamon Press, 1989.
58. Liddon, S., and Satran, R. Disulfiram (Antabuse) psychosis. American Journal of Psychiatry, 123:1284-1289, 1967.
59. Ling, W., and Shoptaw, S. Research in pharmacotherapy for substance abuse: Where are we? Where are we going? Journal of Addiction Medicine, in press.
60. Linszen, D.H.; Dingemans, P.M.; and Lenior, M.E. Cannabis abuse and the course of recent-onset schizophrenic disorders. Archives of General Psychiatry, 51:273-279, 1994.
61. Marchesi, G.F.; Santone, G.; Cotani, P.; Giordano, A.; and Chelli, F. Naltrexone in chronic negative schizophrenia. [Abstract] Clinical Neuropharmacology, 15:56-57, 1992.
62. McLellan, A.T.; Luborsky, L.; Woody, G.E.; and O'Brien, C.P. An improved diagnostic evaluation instrument for substance abuse patients: The addiction severity index. Journal of Nervous and Mental Disease, 168:26-33, 1980.
63. Miller, F., and Tanenbaum, J. Drug abuse in schizophrenia. Hospital and Community Psychiatry, 40(8):847-849, 1989.
64. Mueser, K.T.; Yarnold, P.R.; Levinson, H.S.; Singh, H.; Bellack, A.S.; Kee, K.; Morrison, R.L.; and Yadalam, K.G. Prevalence of substance abuse in schizophrenia: Demographics and clinical correlates. Schizophrenia Bulletin, 16(1):31-51, 1990.
65. Negrete, J.C.; Knapp, W.P.; Douglas, D.E.; and Smith, B. Cannabis affects the severity of schizophrenic symptoms: Results of a clinical survey. Psychological Medicine, 16:515-520, 1986.
66. 2 receptor occupancy in relation to clozapine serum concentration: A PET study of schizophrenic patients. American Journal of Psychiatry, 152(10):1444-1449, 1995.
67. Olivera, A.A.; Kiefer, M.W.; and Manley, N.K. Tardive dyskinesia in psychiatric patients with substance abuse disorders. American Journal of Drug and Alcohol Abuse, 16:57-66, 1990.
68. O'Malley, S.; Jaffe, A.; and Chang, G. Naltrexone and coping skill therapy for alcohol dependence. Archives of General Psychiatry, 49:881-887, 1992.
69. Overall, J.E., and Gorham, D.R. The Brief Psychiatric Rating Scale. Psychological Reports, 10:799-812, 1962.
70. Peralta, V., and Cuesta, M.J. Negative symptoms in schizophrenia: A confirmatory factor analysis of competing models. American Journal of Psychiatry, 152(10):1450-1457, 1995.
71. Schneier, F.R., and Siris, S.G. A review of psychoactive substance use and abuse in schizophrenia: Patterns of drug choice. Journal of Nervous and Mental Disease, 175:641-652, 1987.
72. 2-like dopamine receptor agonists. Science, 271(5255):1586-1589, 1996.
73. Serper, M.R.; Alpert, M.; Richardson, N.A.; Dickson, S.; Allen, M.H.; and Werner, A. Clinical effects of recent cocaine use on patients with acute schizophrenia. American Journal of Psychiatry, 152(10):1464-1469, 1995.
74. Sevy, S.; Kay, S.R.; Opler, L.A.; and Praag, H.M. Significance of cocaine history in schizophrenia. Journal of Nervous and Mental Disease, 178:642-648, 1990.
75. Shaner, A.; Khalsa, H.; Roberts, L.J.; Wilkins, J.N.; Anglin, D.; and Hsieh, S.C. Unrecognized cocaine using among schizophrenic patients. American Journal of Psychiatry, 150(5):758-762, 1993.
76. Shaner, A.; Mintz, J.; Eckman, T.A.; Roberts, L.J.; Wilkins, J.N.; Tucker, D.E.; and Tsuang, J. Disability income, cocaine use and repeated hospitalizations among schizophrenic cocaine abusers: A government-sponsored revolving door? New England Journal of Medicine, 333:777-783, 1995.
77. Shaner, A.; Roberts, L.J.; Eckman, T.A.; Wilkins, J.N.; and Mintz, J. Monetary reinforcement of cocaine abstinence in cocaine dependent schizophrenic patients. Psychiatric Services, in press.
78. Siris, S.G.; Kane, J.M.; Frechen, K.; Sellew, A.P.; Mandell, J.; and Fasano-Dube, B. Histories of substance abuse in patients with post-psychotic depressions. Comprehensive Psychiatry, 29:550-557, 1988a.
79. Siris, S.G.; Mason, S.E.; Bermanzohn, P.C.; Shuwall, M.A.; and Aseniero, M.A. Dual-diagnosis/psychiatric comorbidity of drug dependence: Epidemiology and treatment. Psychopharmacology Bulletin, 29(1):127-132, 1993.
80. Siris, S.G.; Sellew, A.P.; Frechen, K.; Cooper, T.B.; Mandell, J.; and Casey, E. Antidepressants in the treatment of post-psychotic depression in schizophrenia: Drug interactions and other considerations. Clinical Chemistry, 34(5):837-840, 1988b.
81. Soyka, M., and Sand, P. Successful treatment with flupenthixol decanoate of a patient with both schizophrenia and alcoholism. Pharmacopsychiatry, 28(2):64-65, 1995.
82. Spitzer, R.L.; Williams, J.B.W.; Gibbon, M.; and First, M.B. Structured Clinical Interview for DSM-III-R-Patient Version. New York, NY: Biometrics Research Department, New York State Psychiatric Institute, 1988.
83. Tandon, R., and DeQuardo, J.R. Treatment of schizophrenia with anticholinergic medications. [Letter] American Journal of Psychiatry, 152(5):814-815, 1995.
84. Treffert, D.A. Marijuana use in schizophrenia: A clear hazard. American Journal of Psychiatry, 135(10):1213-1215, 1978.
85. van Kammen, D.P., and Boronow, J.J. Dextroamphetamine diminished negative symptoms in schizophrenia. International Clinical Journal of Psychopharmacology, 3:111-121, 1988.
86. Volpicelli, J.; Alterman, A.; Hayashida, M.; and O'Brien, C. Naltrexone in the treatment of alcohol dependence. Archives of General Psychiatry, 49:876-880, 1992.
87. Welch, E.B., and Thompson, D.F. Opiate antagonists for the treatment of schizophrenia. Journal of Clinical Pharmacy and Therapeutics, 19:279-283, 1994.
88. Weller, R.A., and Weller, E.B. Tricyclic antidepressants in prepubertal depressed children: Review of the literature. Hillside Journal of Clinical Psychiatry, 8(1):46-55, 1986.
89. Wilkins, J.N.; Gorelick, D.A.; Levine, D.; Gold, J.; von Raffay, V.; Tucker, D.E.; Roberts, L.J.; Eckman, T.A.; Racenstein, M.; Shaner, A.L.; Ashofteh, A.; Jerger, D.; and Li, S.-H. Double-blind trial of desipramine for treatment of cocaine-abusing schizophrenics. In: Harris, L.S., ed. Problems of Drug Dependence, 1995: Proceedings of the 57th Annual Scientific Meeting. Rockville, MD: U.S. Department of Health and Human Services, National Institutes of Health, National Institute on Drug Abuse, 1996. p. 325.
90. Wilkins, J.N.; Gorelick, D.A.; Shaner, A.L.; Setoda, D.Y.; von Raffay, V.; and Tucker, D.E. Cocaine and marijuana effects in schizophrenia: In: New Research Program and Abstracts: Proceedings of the 144th Meeting of the American Psychiatric Association. Washington, DC: American Psychiatric Association, 1993. p. 165.
91. Wilkins, J.N.; Shaner, A.L.; Patterson, C.M.; Setoda, D.; and Gorelick, D.A. Discrepancies between patient report, clinical assessment, and urine analysis in psychiatric patients during inpatient admission. Psychopharmacology Bulletin, 27(2):149-154, 1991.
92. Wolkowitz, O.M., and Pickar, D. Benzodiazepines in the treatment of schizophrenia: A review and reappraisal. American Journal of Psychiatry, 148(6):714-726, 1991.
93. Zaretsky, A.; Rector, N.A.; Seeman, M.V.; and Fornazzari, X. Current cannabis use and tardive dyskinesia. Schizophrenia Research, 11:3-8, 1993.
94. Ziedonis, D.M.; Fisher, W.; Harris, P.; Trudeau, K.; Rao, S.; and Kosten, T.R. Adjunctive selegiline in the treatment of cocaine-abusing schizophrenics. In: Harris, L.S., ed. Problems of Drug Dependence, 1995: Proceedings of the 57th Annual Scientific Meeting. Rockville, MD: U.S. Department of Health and Human Services, National Institutes of Health, National Institute on Drug Abuse, 1996. p. 325.
95. Ziedonis, D.M., and George, T.P. Schizophrenia and nicotine use: Report of a pilot smoking cessation program and review of neurobiological and clinical issues. Schizophrenia Bulletin, 23(3):247-254, 1997.
96. Ziedonis, D.M.; Kosten, T.R.; Glazer, W.M.; and Frances, R.J. Nicotine dependence and schizophrenia. Hospital and Community Psychiatry, 45(3):204-206, 1994.
97. Ziedonis, D.M.; Richardson, T.; Lee, E.; Petrakis, I.; and Kosten, T.R. Adjunctive desipramine in the treatment of cocaine abusing schizophrenics. Psychopharmacology Bulletin, 28(3):309-314, 1992.
98. Zweben, J.E., and O'Connell, K. Strategies for breaking marijuana dependence. Journal of Psychoactive Drugs, 24(2):165-171, 1992.